Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 5Thyroid Cancer, Papillary 2Carcinoma, Non-Small-Cell Lung 2Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1Sexual Dysfunction, Physiological 1Neoplasms 1Gastrointestinal Neoplasms 1Eunuchism 1Erectile Dysfunction 1Carcinoma, Medullary 1Cachexia-Anorexia Syndrome 1Breast Neoplasms 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 3Capecitabine 3lutetium Lu 177 dotatate 2lenvatinib 2cabozantinib 2Thyroidectomy 2Temozolomide 2Sorafenib 2Magnetic Resonance Spectroscopy 2High-Energy Shock Waves 2veliparib 1vatalanib 1vandetanib 1temsirolimus 1selpercatinib 1sacubitril and valsartan sodium hydrate drug combination 1ponatinib 1pentetreotide 1pasireotide 1gallium Ga 68 dotatate 1fluorodopa F 18 1fludarabine 1cemiplimab 1Vinorelbine 1Thalidomide 1Surgical Procedures, Operative 1Sunitinib 1Specimen Handling 1Sirolimus 1Semaxinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Medullary × selpercatinib × Clear all
NCT04759911 2026-05-20

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡